TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02135393

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 13C5-folic acid or 13C5-6S-5-FormylTHF
Description: Subjects with an insitu transjugular intrahepatic porto systemic stent shunt assigned to receive either a physiological 500 nmol (220 µg folic acid equivalent) dose of 13C5-folic acid or 13C5-6S-5-FormylTHF at the time of routine shunt venography to check patency followed by portal venous sampling at pre defined time points for 85 minutes and then given 13C5-6S-5-FormylTHF ator 13C5-folic acid at their next annual venography patency check with portal venous sampling at pre defined time points for 85 minutes
Study: NCT02190838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: per os 850 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: per os 3 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: IV 1 hour 1000 mg/m\^2 once in 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: IV 1 hour 1000 mg/m\^2 once in 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: IV 1 hour 1000 mg/m\^2 once in 28 days
Study: NCT03478579

Intervention type: OTHER
Intervention: observational
Description: No intervention, it is observational study
Study: NCT00117611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-IgE antibody omalizumab or placebo
Description: given subcutaneously oce or twice monthly depending on dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-IgE antibody omalizumab or placebo
Description: given subcutaneously oce or twice monthly depending on dose
Study: NCT02298374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homecare reablement
Study: NCT03296735

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Contralateral tilt
Description: The operation table will be tilted 20 degrees left laterally.
Study: NCT02653235

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Salmonella typhi vaccination

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02298374

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Study: NCT02980172

Intervention type: OTHER
Intervention: Pain evaluation
Description: Evaluation of pain using a numerical scale (1 to 10)
Study: NCT03765190

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Radiation: Proton Therapy+PD-1 Ab
Description: combination of proton radiotherapy with PD-1 antibody
Study: NCT02225197

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife Radiosurgery
Description: 25 Gy delivered in 5 fractions of 5 Gy per fraction
Study: NCT01516073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: FP BID for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: FP BID for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: FP BID for 12 weeks
Study: NCT02634736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exergame plus usual treatment
Description: An individualised \[i.e. frequency and duration will be set according to each participant's baseline levels\] Exergame programme incorporated into participant's normal routines plus usual falls prevention treatment (prescribed by the physiotherapists).
Study: NCT03552367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized structured exercise program
Description: The type of exercise offered to patients in this arm is precisely designed for obese patients according to age and physical fitness parameters. Patients are monitored using a heart rate monitor to evaluate treatment adherence and compliance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non personalized non-structured exercise program
Description: The type of exercise is non-structured and patients' heart rate is not monitored. Patients receive exercise recommendations without any personalization according to their fitness parameters
Study: NCT03510338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual sildenafil
Description: 100 mg biphasic sildenafil tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual sildenafil
Description: 100 mg biphasic sildenafil tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral sildenafil
Description: 50 mg oral sildenafil (Viagra)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral sildenafil
Description: 50 mg oral sildenafil (Viagra)
Study: NCT00448227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: famciclovir
Description: Administered orally as a single individualized dose between 25-200 mg based on body weight.
Study: NCT01516073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: FP BID for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: FP BID for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone Propionate
Description: FP BID for 12 weeks
Study: NCT03297814

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet lysate
Description: Intramuscular injection of platelet lysate

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intramuscular injection of normal saline
Study: NCT04634890

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise intervention
Description: Supervised exercise intervention composed of mixed aerobic and strength activities, with the frequency of 3 sessions per week for 12 weeks, for a total number of trainings of 36.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise intervention
Description: Supervised exercise intervention composed of mixed aerobic and strength activities, with the frequency of 3 sessions per week for 12 weeks, for a total number of trainings of 36.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise intervention
Description: Supervised exercise intervention composed of mixed aerobic and strength activities, with the frequency of 3 sessions per week for 12 weeks, for a total number of trainings of 36.
Study: NCT03113916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Lifestyle Intervention
Description: A culturally tailored behavioral intervention.
Study: NCT02752204

Intervention type: DRUG
Group type: OTHER
Intervention: AZD 2014
Description: AZD2014 125mg BD - 2 days on 5 days off in a 28 day cycle

Intervention type: DRUG
Group type: OTHER
Intervention: AZD 2014
Description: AZD2014 125mg BD - 2 days on 5 days off in a 28 day cycle

Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab
Description: Rituximab 375mg/m2 will be administered intravenously on day 1 of a 28 day cycle for a total of 6 cycles.
Study: NCT04192370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol 600mg
Description: All subjects will receive 600mg of oral cannabidiol for 3 days in an open-label fashion. Cannabidiol will be provided using Epidiolex™ oral solution 100mg/mL, and the drug will be procured by the Brigham and Women's Hospital (BWH) Investigational Drug Services (IDS) pharmacy. The first dose will be administered at the BWH Center for Clinical Investigation, while doses 2 and 3 will be self-administrated at home. The CBD will be repacked in pre-drawn syringes for the subjects to self-administer at home.
Study: NCT04187677

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sensory Training
Description: The sensory training group includes sensory-oriented interventions and exercises unlike the other classical hand therapy group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: classical hand therapy
Description: classical hand therapy
Study: NCT02891161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: 1500 mg Q4 weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: 1500 mg Q4 weekly

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 64.8 Gy, 36 daily fractions on weekdays over about 7 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 64.8 Gy, 36 daily fractions on weekdays over about 7 weeks
Study: NCT04220827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IP
Study: NCT03899805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: The ability of chemotherapy to kill cancer cells depends on its ability to halt cell division. Usually, the drugs work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die. The faster the cells are dividing, the more likely it is that chemotherapy will kill the cells, causing the tumor to shrink. They also induce cell suicide (self-death or apoptosis).
Study: NCT01675219

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blue light TUR-BT
Description: photodynamic transurethral bladder tumor resection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: optimized MMC
Description: six weekly optimized mitomycin-C instillations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: optimized MMC
Description: six weekly optimized mitomycin-C instillations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: single immediate chemotherapy instillation
Description: single immediate post TUR-BT epirubicin (2mg/ml, total of 100 ml) instillation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single immediate chemotherapy instillation
Description: single immediate post TUR-BT epirubicin (2mg/ml, total of 100 ml) instillation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single immediate chemotherapy instillation
Description: single immediate post TUR-BT epirubicin (2mg/ml, total of 100 ml) instillation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single immediate chemotherapy instillation
Description: single immediate post TUR-BT epirubicin (2mg/ml, total of 100 ml) instillation
Study: NCT02361749

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin
Description: Injection of Botulinum toxin under general anesthesia. Four injections will be given into the anal sphincter into the four quadrants in one session.
Study: NCT04266769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LightForce Orthodontic System
Description: The LightForce Orthodontic System is a a digital treatment planning platform and patient-specific 3D printed polycrystalline alumina brackets for the treatment of malocclusion
Study: NCT02423772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy + Mindfulness-Based Relapse Prevention + Treatment as Usual (TAU)
Study: NCT02887573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Free-residue nutrients
Description: This trial evaluated the efficiency of free-residue nutrients for the bowel prepartion of CCE.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low fiber diet
Description: Low fiber diet often used in the bowel prepartion of CCE. In this study, it is the control group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colon capsule endoscopy
Description: In the study,all patients should undergo two colonoscopies.The first is for examinations and the second for therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colon capsule endoscopy
Description: In the study,all patients should undergo two colonoscopies.The first is for examinations and the second for therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2L PEG
Description: 2L PEG are laxatives for experiment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4L PEG
Description: 4L PEG are laxatives in the control group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Description: These PEG are for boosters. All patients will take 0.75L and 0.5L PEG for two boosters.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Description: These PEG are for boosters. All patients will take 0.75L and 0.5L PEG for two boosters.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosapride citrate
Description: 5mg mosapride citrate are used to promote gastric motivity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosapride citrate
Description: 5mg mosapride citrate are used to promote gastric motivity.
Study: NCT03899805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: The ability of chemotherapy to kill cancer cells depends on its ability to halt cell division. Usually, the drugs work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die. The faster the cells are dividing, the more likely it is that chemotherapy will kill the cells, causing the tumor to shrink. They also induce cell suicide (self-death or apoptosis).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: The ability of chemotherapy to kill cancer cells depends on its ability to halt cell division. Usually, the drugs work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die. The faster the cells are dividing, the more likely it is that chemotherapy will kill the cells, causing the tumor to shrink. They also induce cell suicide (self-death or apoptosis).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells.
Study: NCT04679584

Intervention type: OTHER
Intervention: Observation of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings
Description: Oberservatory Cohorts focusing (I) on subjects after SARS-CoV-2 infection that are recruited from the general population (POP), and on subjects with acute SARS-CoV-2 infections recruited (II) in university hospital high-care settings or (III) general health care

Intervention type: OTHER
Intervention: Observation of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings
Description: Oberservatory Cohorts focusing (I) on subjects after SARS-CoV-2 infection that are recruited from the general population (POP), and on subjects with acute SARS-CoV-2 infections recruited (II) in university hospital high-care settings or (III) general health care

Intervention type: OTHER
Intervention: Observation of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings
Description: Oberservatory Cohorts focusing (I) on subjects after SARS-CoV-2 infection that are recruited from the general population (POP), and on subjects with acute SARS-CoV-2 infections recruited (II) in university hospital high-care settings or (III) general health care
Study: NCT01371201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: sunitinib 37.5 mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 37.5 mg per day
Study: NCT03683355

Intervention type: RADIATION
Intervention: 18F-FDG PET/CT
Description: 18F-FDG PET/CT and blood cultures will be performed at 3-month follow-up after TAVR Patients with positive 18F-FDG PET/CT (moderate or intense radiolabeled tracer uptake) will be scheduled for a second 18F-FDG PET/CT at 6-month follow-up.
Study: NCT01872715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oracea
Study: NCT00112723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study: NCT00501241

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ATI-7505
Description: Tablet,placebo, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-7505
Description: ATI-7505 20 mg BID for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-7505
Description: tablet, 40 mg, BID, $ weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-7505
Description: 80 mg ATI-7505, BID for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-7505
Description: 120 mg ATI-7505, BID, for 4 weeks
Study: NCT03034733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: intravenous dexamethasone, two groups: 0,15 mg/kg, 0,25 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: intravenous dexamethasone, two groups: 0,15 mg/kg, 0,25 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride, (24)NaCl 0,9%
Description: intravenous placebo
Study: NCT05698940

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infundibultomy
Description: Infundibultomy on one side of patient

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Infundibultomy
Description: Infundibultomy on one side of patient
Study: NCT04763317

Intervention type: GENETIC
Intervention: Prostate cancer risk gene panel
Description: A list of genes created by study experts, thought to increase the risk of prostate cancer from from review previous research, this list is regularly reviewed for accuracy

Intervention type: GENETIC
Intervention: Prostate cancer risk gene panel
Description: A list of genes created by study experts, thought to increase the risk of prostate cancer from from review previous research, this list is regularly reviewed for accuracy
Study: NCT04222244

Intervention type: OTHER
Intervention: No intervention will be administered. We are only performing tests and measures.
Description: No intervention will be administered. We are only performing tests and measures.

Intervention type: OTHER
Intervention: No intervention will be administered. We are only performing tests and measures.
Description: No intervention will be administered. We are only performing tests and measures.
Study: NCT02307123

Intervention type: PROCEDURE
Intervention: Intubation
Description: HEMS physician prehospital intubation
Study: NCT00800124

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cemented Landos prosthesis vs. uncemented Landos prosthesis
Description: randomization between the cemented and non-cemented prosthesis.
Study: NCT02223793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information on high risk factor levels and lifestyle advice
Description: This arm of high risk participants will be informed about their measured levels of the different cardiovascular risk factors. They will also receive information on how to lower their levels in 8 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No information on high risk factor levels but lifestyle advice
Description: In this arm, participants will have delayed information on their risk factor levels, but they will receive general advices on how to lower levels in 8 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No information on high risk factor levels, nor lifestyle advice
Description: In this arm, participants will have delayed information on both their risk factor levels and general information on how to lower risk factor levels.
Study: NCT04364880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TBS
Description: Theta-burst stimulation (TBS) is a novel repetitive transcranial magnetic stimulation (rTMS)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The sham-TBS coil produced a similar sound without a magnetic pulse.
Study: NCT04516213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enteral Formula With (PHGG)
Description: Pediatric subjects will be fed a Peptide-based Enteral Formula With Partially Hydrolyzed Guar Gum (PHGG)
Study: NCT03201094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation (NMES)
Description: Neuromuscular electrical stimulation twice daily during study period.
Study: NCT03179748

Intervention type: DRUG
Intervention: turoctocog alfa
Description: Patients will be treated with commercially available turoctocog alfa according to local clinical practice at the discretion of the physician
Study: NCT03827005

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: NOW Foods, Bloomingdale, IL

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L-arginine
Description: NOW Foods, Bloomingdale, IL

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: InHealth Specialty Pharmacy, Fargo, ND
Study: NCT01244984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/GW642444 Inhalation Powder
Description: Fluticasone Furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
Study: NCT03201094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation (NMES)
Description: Neuromuscular electrical stimulation twice daily during study period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Protein Supplementation
Description: High protein supplementation with whey protein shakes taken three times a day during study period.
Study: NCT01244984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate Inhalation Powder
Description: Fluticasone Furoate inhalation powder inhaled orally once daily for 52 weeks
Study: NCT01262495

Intervention type: OTHER
Group type: OTHER
Intervention: cryopreservation
Description: cryopreservation of testicular tissue
Study: NCT03201094

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Protein Supplementation
Description: High protein supplementation with whey protein shakes taken three times a day during study period.
Study: NCT02017834

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical resection
Description: neck dissection and tumour resection will be performed either with or without the harmonic scalpel as an adjunct.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical resection
Description: neck dissection and tumour resection will be performed either with or without the harmonic scalpel as an adjunct.
Study: NCT01348581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Marigen Wound Dressing
Description: The dressing is changed at least twice a week, with no more than five days between dressing changes. It is extremely important that the dressings are changed sufficiently often. On highly exuding ulcers the three or four dressing changes per week may be necessary. Duration is four weeks.